Treatment of @entity1694 with khellin and XXXX .

@entity1 @entity137 @entity6337 @entity1694 @entity73133 @entity1129 @entity272 @entity73132
Twenty-eight @entity1 with @entity1694 were treated with a new photochemotherapeutic regimen using khellin, a @entity73132 , as photosensitizer, together with @entity1129 ( @entity1129 ) irradiation. Twenty-five @entity1 received khellin orally and three @entity1 were treated with topical khellin. Treatments were given three times weekly. As opposed to psoralens, @entity73133 did not induce @entity272 with @entity1129 but it induced repigmentation similar to psoralens. The treatment success strongly depended on the number of treatments. More than 70% repigmentation was achieved in 41% of the @entity1 who had received 100 to 200 treatments. This success rate is comparable to the rate obtained with psoralens. Seven @entity1 experienced a mild elevation of liver transaminases within the early treatment phase and their treatments were discontinued. No long-term internal organ or skin @entity137 was observed. The major advantage of khellin is that it does not lead to @entity6337 skin erythema and thus can be considered safe for home treatment. Because of its photochemistry it may be considered less hazardous than psoralens regarding mutagenicity and carcinogenicity.
